DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%

Q1 2026 earnings call: 15% revenue growth, Prime coverage expansion, G7 15 Day rollout, and raised margin outlook.

DexCom Q1 2026 Earnings Call Transcript

DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...

Dexcom Reaffirms Full-Year Forecast After Topping Quarterly Estimates

Medical device maker Dexcom ⁠on ⁠Thursday reiterated its ⁠full-year revenue forecast after beating Wall Street estimates ​for ...
Hosted on MSN

Dexcom gains Prime Therapeutics coverage, lifts 2026 margin outlook

Dexcom reported strong Q1 2026 growth and raised its operating margin outlook after securing Prime Therapeutics coverage for all people with diabetes. The move expands commercial access to over 7 ...
Drug Delivery Business

Dexcom stock dips after hours despite Q1 beats, 15% sales growth

Dexcom (Nasdaq:DXCM) today posted first-quarter financial results that came in ahead of the Wall Street forecast.